Agent Orange Exposure, Cytogenetics, and Clinical Outcomes in Multiple Myeloma and MGUS Patients

被引:0
|
作者
Kulkami, P. [1 ,2 ]
Hall, J. A. [1 ,2 ]
Copeland, L. A. [3 ,4 ]
Nangrani, A. [1 ]
Dodlapati, J. [1 ,2 ]
机构
[1] Cent Texas Vet Hlth Care Syst, Temple, TX USA
[2] Baylor Scott & White Hlth, Dallas, TX USA
[3] VA Cent Western Massachusetts Healthcare Syst, Northampton, MA 01062 USA
[4] Univ Massachusetts, Chan Med Sch, Worcester, MA 01106 USA
来源
JOURNAL OF MILITARY AND VETERANS HEALTH | 2024年 / 32卷 / 02期
关键词
MONOCLONAL GAMMOPATHY; POOR-PROGNOSIS; LONG-TERM; CHROMOSOME-13; DELETION;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background While considerable research has examined transformation from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) and the association of Agent Orange (AO) with MM, adverse cytogenetics are understudied. Purpose To evaluate associations between AO and adverse cytogenetics or other poor prognostic factors such as abnormal light chain ratio in aged veterans with MM. Materials and methods Vietnam -era Veterans diagnosed with MM or MGUS at a Veterans Health Administration site were identified. Chart review abstracted presence of 17p13, t(4;14), t(14;16), t(14;20), and Gain lq by FISH (dubbed FISH-5) and q13/13q14 deletion, kappa/lambda ratio <.03 / >32 for MM (<.256 / >1.65 for MGUS), and bone marrow plasma cell percentage for MM. Results Among 238 veterans, 70 had MM and 192 MGUS; 24 had both diagnoses (transformation). In MGUS, AO was not associated with transformation, although kappa/lambda ratio was. In MM, Hispanic veterans had more AO exposure. Survival was unassociated with AO or adverse cytogenetics, while Hispanic veterans experienced increased mortality. Conclusion Our study explored cytogenetics in MM among surviving Vietnam Veterans with and without AO exposure. Although Hispanic veterans were more likely to have AO exposure, Hispanic ethnicity but not AO was associated with poorer survival.
引用
收藏
页码:27 / 33
页数:7
相关论文
共 43 条
  • [21] Heavy plus light chain monitoring correlates with clinical outcome in multiple myeloma patients
    Michallet, M.
    Chapuis-Cellier, C.
    Dejoie, T.
    Lombard, C.
    Caillon, H.
    Sobh, M.
    Moreau, P.
    Attal, M.
    Avet-Loiseau, H.
    LEUKEMIA, 2018, 32 (02) : 376 - 382
  • [22] An interactive nomogram based on clinical and molecular signatures to predict prognosis in multiple myeloma patients
    Liu, Linxin
    Qu, Jian
    Dai, Yuxin
    Qi, Tingting
    Teng, Xinqi
    Li, Guohua
    Qu, Qiang
    AGING-US, 2021, 13 (14): : 18442 - 18463
  • [23] Comparison of outcomes by race among a population-based matched sample of multiple myeloma patients
    Greteman, Breanna B.
    Tomasson, Michael H.
    Kahl, Amanda R.
    Wahlen, Madison M.
    Bates, Melissa L.
    Strouse, Christopher
    Charlton, Mary E.
    CANCER CAUSES & CONTROL, 2024, : 433 - 442
  • [24] Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma
    Abeykoon, Jithma P.
    Vaxman, Julia
    Patel, Sanjay V.
    Kumar, Shaji
    Malave, Gabriella C.
    Young, Kimberly S.
    Ailawadhi, Sikander
    Larsen, Jeremy T.
    Dispenzieri, Angela
    Muchtar, Eli
    Gonsalves, Wilson I.
    Kourelis, Taxiarchis
    Leung, Nelson
    Warsame, Rahma
    Go, Ronald S.
    Bergsagel, Leif
    Lacy, Martha Q.
    Rajkumar, S. Vincent
    Gertz, Morie A.
    Kapoor, Prashant
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (01) : 95 - 99
  • [25] Racial and age-related disparities in early mortality affect the outcomes of multiple myeloma patients
    Covut, Fahrettin
    Driscoll, James Joseph
    Cooper, Brenda
    Gallogly, Molly
    De Lima, Marcos
    Malek, Ehsan
    LEUKEMIA, 2021, 35 (01) : 250 - 254
  • [26] Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma
    Wei, GuoQing
    Wang, LiJun
    Yang, HanJin
    Han, XiaoYan
    Zheng, GaoFeng
    Zheng, WeiYan
    Sun, Jie
    Shi, JiMin
    Wu, WenJun
    Zhao, Yi
    He, DongHua
    Wang, Bo
    Cai, Zhen
    He, JingSong
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2017, 6
  • [27] Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma
    Wadhera, Rishi K.
    Kyle, Robert A.
    Larson, Dirk R.
    Dispenzieri, Angela
    Kumar, Shaji
    Lazarus, Hillard M.
    Rajkumar, S. Vincent
    BLOOD, 2011, 118 (11) : 2985 - 2987
  • [28] RETRACTED: Analysis of Coagulation Abnormality in Patients with Multiple Myeloma and Its Clinical Significance (Retracted Article)
    Pan, Pengji
    Liu, Junxia
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2022, 2022
  • [29] Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study
    Oh, Sukjoong
    Koo, Dong Hoe
    Kwon, Min-Jung
    Kim, Kihyun
    Suh, Cheolwon
    Min, Chang-Ki
    Yoon, Sung-Soo
    Shin, Ho-Jin
    Jo, Deog-Yeon
    Kwak, Jae-Yong
    Kim, Jin Seok
    Sohn, Sang Kyun
    Joo, Young-Don
    Eom, Hyeon-Seok
    Kim, Sung-Hyun
    Kim, Yang Soo
    Kim, ChulSoo
    Mun, Yeung-Chul
    Kim, Hawk
    Lee, Dong Soon
    Lee, Jae Hoon
    ANNALS OF HEMATOLOGY, 2014, 93 (08) : 1353 - 1361
  • [30] Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis
    Atrash, Shebli
    Flahavan, Evelyn M.
    Xu, Tao
    Ma, Esprit
    Karve, Sudeep
    Hong, Wan-Jen
    Jirau-Lucca, Gilbert
    Nixon, Michael
    Ailawadhi, Sikander
    BLOOD CANCER JOURNAL, 2022, 12 (03)